Coexisting DCIS and phyllodes breast tumors in Young Chinese women: Case series

Abstract

Highlights Breast cystosarcomaphyllodes tumors are rare and can be benign or malignant. These tumors can harbor carcinomas, although the incidence is extremely rare. Although challenging, the detection of a carcinoma component in phyllodes tumor is important, as it can dictate the need for lymph node sampling and possible adjuvant therapies such as radiation and systemic management.

High-grade ductal carcinoma in-situ detected by microcalcification within borderline phyllodes tumour: A report of a case and literature review

“…the remaining 3 cases with invasive carcinoma involvement did not have microcalci cations (two cases of LCIS + invasive lobular carcinoma and a case of IDC). Both benign looking specks (21) and suspicious coarse punctuated clusters of microcalci cations (23), such as those seen in this case, had been described in carcinomas.…”

“…Including this case study, 47 published cases were analysed (Table 1) (2,(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41). All of them were female patients aged between 19 and 80 years old (mean age = 47.6 years old and median age = 49 years old).…”

Synchronous Luminal A Ductal Carcinoma In Situ in a Recurrent Benign Phyllodes Tumor Diagnosed Preoperatively: An Unusual Presentation of a Rare Neoplasm

“…It may present within the PT or as a separate lesion near the PT, in the ipsilateral or contralateral breast [5,7]. Moreover, a coexisting DCIS within PT has to be differentiated from carcinosarcoma (a subtype of metaplastic carcinoma) where epithelial markers are absent [2]. Hence, the diagnosis of coexisting DCIS in PT is made after histological subtyping of PT and assessment of coexisting DCIS by immunohistochemistry.…”

“…Histologically, there is a biphasic proliferation of stromal and epithelial components, arranged in a leaf-like pattern, which gives it the name phyllodes [1]. PT accounts for only 0.3-0.9% of all breast tumors [1] and 2-3% of fibroepithelial breast tumors [2]. The World Health Organization (WHO) has classified PT based on histological characteristics of the stromal component into benign, borderline, and malignant subtypes, which helps in the prognostication of the clinical course and recurrence risk [3].…”

Malignant phyllodes tumors of the breast associating malignancy of both mesenchymal and epithelial components (invasive or in situ ductal carcinoma)

“…Presence of the malignancy of both epithelial [under the form of invasive carcinoma or ductal carcinoma in situ (DCIS)] and mesenchymal components at the same time is an even rarer finding. That is why most of the literature data refers to single case presentations [3][4][5][6] or small series presentations [7][8][9][10] but also that is why it is a challenging diagnostic for the pathologists [1,2,11]. It is believed that malignancy of the epithelial component of phyllodes tumor occurs in less than 1% of all phyllodes tumors [8].…”